

Health-related Quality of Life and Pain in the MAGNITUDE Study of Niraparib With Abiraterone Acetate and Prednisone in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations

Dana E Rathkopf, Guilhem Roubaud, Kim N Chi, Shahneen Sandhu, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J Small, Andrea J Pereira de Santana Gomes, Marniza Saad, Elena Castro, Deniz Tural, Gary E Mason, Katherine B Bevans, Jeremiah J Trudeau, Peter Francis, George Wang, Angela Lopez-Gitlitz, Matthew R Smith

SUPPLEMENTAL TABLE: Minimum clinically important differences

PRO total score or domain	Threshold for definition of progression/deterioration (decrease from baseline)
BPI-SF	Increase from baseline
Worst pain (BPI-SF question #3)	$\geq 30\%$ of baseline ≥ 2 points
Pain interference score (combination of BPI-SF scale scores 9a-9g)	\geq half standard deviation of baseline
FACT-P	Decrease from baseline
FACT-P total scale	10
Physical well-being	3

BPI-SF, Brief Pain Inventory–Short Form; FACT-P, Functional Assessment of Cancer Therapy–Prostate; PRO, patient-reported outcome.

